KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBT Margin: 2009-2025

Historic EBT Margin for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to 8.68%.

  • Charles River Laboratories International's EBT Margin fell 36.00% to 8.68% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.55%, marking a year-over-year decrease of 1332.00%. This contributed to the annual value of 2.30% for FY2024, which is 1178.00% down from last year.
  • Per Charles River Laboratories International's latest filing, its EBT Margin stood at 8.68% for Q3 2025, which was up 25.41% from 6.92% recorded in Q2 2025.
  • Charles River Laboratories International's EBT Margin's 5-year high stood at 22.27% during Q4 2022, with a 5-year trough of -21.62% in Q4 2024.
  • Its 3-year average for EBT Margin is 7.69%, with a median of 9.79% in 2024.
  • As far as peak fluctuations go, Charles River Laboratories International's EBT Margin surged by 419bps in 2022, and later crashed by 4,222bps in 2024.
  • Quarterly analysis of 5 years shows Charles River Laboratories International's EBT Margin stood at 18.08% in 2021, then spiked by 419bps to 22.27% in 2022, then tumbled by 168bps to 20.59% in 2023, then tumbled by 4,222bps to -21.62% in 2024, then plummeted by 36bps to 8.68% in 2025.
  • Its EBT Margin was 8.68% in Q3 2025, compared to 6.92% in Q2 2025 and 3.66% in Q1 2025.